WO2010142678A3 - Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide - Google Patents
Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide Download PDFInfo
- Publication number
- WO2010142678A3 WO2010142678A3 PCT/EP2010/058006 EP2010058006W WO2010142678A3 WO 2010142678 A3 WO2010142678 A3 WO 2010142678A3 EP 2010058006 W EP2010058006 W EP 2010058006W WO 2010142678 A3 WO2010142678 A3 WO 2010142678A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbamoylamino
- polymorphs
- carboxamide
- phenoxy
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Abstract
The present invention relates to polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]- carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide and pharmaceutical compositions comprising the same.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10722711.8A EP2440531A2 (en) | 2009-06-12 | 2010-06-08 | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide |
IL216649A IL216649A0 (en) | 2009-06-12 | 2011-11-28 | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1395/CHE/2009 | 2009-06-12 | ||
IN1395CH2009 | 2009-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010142678A2 WO2010142678A2 (en) | 2010-12-16 |
WO2010142678A3 true WO2010142678A3 (en) | 2011-03-24 |
Family
ID=42931997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/058006 WO2010142678A2 (en) | 2009-06-12 | 2010-06-08 | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2440531A2 (en) |
IL (1) | IL216649A0 (en) |
WO (1) | WO2010142678A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010299484A1 (en) * | 2009-09-24 | 2012-05-03 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
WO2012071425A1 (en) | 2010-11-22 | 2012-05-31 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sorafenib besylate, and processes for preparations thereof |
US9156789B2 (en) | 2012-05-21 | 2015-10-13 | Hetero Research Foundation | Process for sorafenib tosylate polymorph III |
US20150111929A1 (en) * | 2012-05-23 | 2015-04-23 | Shilpa Medicare Limited | Process for preparing crystalline sorafenib tosylate |
CN103570613B (en) * | 2012-07-18 | 2016-06-15 | 苏州泽璟生物制药有限公司 | The polymorphic form of deuterated ω-diphenyl urea or its salt |
CN106336377A (en) * | 2015-07-17 | 2017-01-18 | 苏州亚宝药物研发有限公司 | Preparation method for crystal form II of sorafenib tosylate |
EP3390362A4 (en) * | 2015-12-14 | 2019-06-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Sorafenib hemi-p-tosylate monohydrate crystal and preparation process thereof |
CN107759517A (en) * | 2016-08-23 | 2018-03-06 | 广州白云山医药集团股份有限公司白云山制药总厂 | A kind of preparation method of Sorafenib Tosylate crystal formation I |
RU2766288C2 (en) * | 2020-03-30 | 2022-03-11 | Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" | Amorphous form of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-n-methylpyridine-2-carboxamide tosylate (versions), method for production and use thereof for treatment of oncological diseases |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026501A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
WO2006034797A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Thermodynamically stable form of bay 43-9006 tosylate |
WO2006094626A1 (en) * | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
WO2007038524A2 (en) * | 2005-09-28 | 2007-04-05 | Ssci, Inc. | Cocrystallization methods |
WO2008008733A2 (en) * | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
CN101584661A (en) * | 2009-06-10 | 2009-11-25 | 北京大学 | Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof |
-
2010
- 2010-06-08 WO PCT/EP2010/058006 patent/WO2010142678A2/en active Application Filing
- 2010-06-08 EP EP10722711.8A patent/EP2440531A2/en not_active Withdrawn
-
2011
- 2011-11-28 IL IL216649A patent/IL216649A0/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026501A1 (en) * | 2004-08-27 | 2006-03-09 | Bayer Pharmaceuticals Corporation | New pharmaceutical compositions for the treatment of cancer |
WO2006034797A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Thermodynamically stable form of bay 43-9006 tosylate |
WO2006094626A1 (en) * | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
WO2007038524A2 (en) * | 2005-09-28 | 2007-04-05 | Ssci, Inc. | Cocrystallization methods |
WO2008008733A2 (en) * | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
CN101584661A (en) * | 2009-06-10 | 2009-11-25 | 北京大学 | Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof |
Non-Patent Citations (2)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2009, WANG, XUEQING ET AL: "Sorafenib self-microemulsifying drug delivery system for oral medication or intravenous injection, and the preparation method and application thereof", XP002613940, retrieved from STN Database accession no. 2009:1482361 * |
PETIT S ET AL: "The Amorphous State", 1 January 2006, 20060101, PAGE(S) 259 - 285, ISBN: 978-3-527-31146-0, XP002481458 * |
Also Published As
Publication number | Publication date |
---|---|
EP2440531A2 (en) | 2012-04-18 |
IL216649A0 (en) | 2012-02-29 |
WO2010142678A2 (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010142678A3 (en) | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide | |
WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
IL194850A (en) | Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol and pharmaceutical compositions comprising same | |
IL233677A (en) | Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments | |
WO2011077043A3 (en) | Phenol derivatives and pharmaceutical or cosmetic use thereof | |
BRPI0915149A2 (en) | Nutritional composition, and uses of a composition, and a dairy product | |
IL224288A (en) | Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof | |
WO2008127646A8 (en) | Transaminase-based processes for preparation of pregabalin | |
WO2012042371A3 (en) | Pharmaceutical composition | |
JO3021B1 (en) | 4-[4-({[ 4- chloro-3- (trifluoromethyl) phenyl] carbamoyl}lamino)-3- fluoromethyl]-N-methylpyridine -2- carboxamide monohydrate | |
WO2010030983A3 (en) | Pyrazole carboxamide inhibitors of factor xa | |
IL210549A (en) | Substituted- quinoxaline-type bridged-piperidine compounds, compositions comprising them and uses thereof for the manufacture of medicaments | |
WO2010147830A3 (en) | Aminothiazole modulators of beta-3-adrenoreceptor | |
EP2613767A4 (en) | Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin | |
WO2010118291A3 (en) | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | |
WO2010141693A3 (en) | Borinic compositions | |
IL222999A (en) | Process for the preparation of pleuromutilins, intermediates and pharmaceutical compositions comprising pleuromutilin compounds | |
HRP20171742T1 (en) | Composition of 2,4,6-trifluoro-n-6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide | |
WO2009115084A3 (en) | Pyrrolopyrimidine derivatives, and use thereof | |
IL209360A (en) | Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma | |
WO2009125409A3 (en) | Fatty acid amides and uses thereof | |
WO2011088160A3 (en) | Novel cyp17 inhibitors | |
PL2504331T3 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
WO2012075015A3 (en) | Oral metronidazole pharmaceutical compositions | |
WO2010006904A3 (en) | Crystalline forms of rabeprazole sodium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10722711 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010722711 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |